Emergent BioSolutions (NYSE:EBS) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Emergent BioSolutions (NYSE:EBS – Get Rating) in a research report issued on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, TheStreet downgraded Emergent BioSolutions from a “c-” rating to a “d” rating in a research report on Monday, February 27th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $36.75.

Emergent BioSolutions Price Performance

NYSE:EBS opened at $9.65 on Thursday. The firm has a market capitalization of $483.85 million, a price-to-earnings ratio of -2.15 and a beta of 0.94. Emergent BioSolutions has a 52-week low of $9.17 and a 52-week high of $45.14. The stock has a fifty day moving average of $12.98 and a 200 day moving average of $15.71. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.70 and a current ratio of 0.98.

Emergent BioSolutions (NYSE:EBS – Get Rating) last released its quarterly earnings results on Monday, February 27th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.62). Emergent BioSolutions had a negative net margin of 19.97% and a negative return on equity of 7.57%. The firm had revenue of $330.70 million for the quarter, compared to analysts’ expectations of $298.23 million. During the same quarter in the previous year, the business earned $4.50 EPS. The company’s revenue for the quarter was down 54.3% on a year-over-year basis. On average, research analysts expect that Emergent BioSolutions will post -0.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Ancora Advisors LLC purchased a new position in shares of Emergent BioSolutions in the first quarter worth about $66,000. Covestor Ltd increased its holdings in shares of Emergent BioSolutions by 43.8% in the first quarter. Covestor Ltd now owns 1,612 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 491 shares during the period. Lazard Asset Management LLC purchased a new position in shares of Emergent BioSolutions in the first quarter worth about $73,000. Captrust Financial Advisors increased its holdings in shares of Emergent BioSolutions by 48.6% in the second quarter. Captrust Financial Advisors now owns 2,772 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 906 shares during the period. Finally, Quantbot Technologies LP bought a new stake in shares of Emergent BioSolutions in the first quarter worth about $117,000. Hedge funds and other institutional investors own 80.44% of the company’s stock.

About Emergent BioSolutions

(Get Rating)

Emergent BioSolutions Inc engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm’s products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV.